Topas Therapeutics
Phase 2Transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology
Founded
2012
Focus
Drug DeliveryNanotechnology
About
Transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology
Funding History
2Total raised: $73M
Series B$48MAndera PartnersJan 15, 2022
Series A$25MBioMedPartnersJul 15, 2019
Company Info
TypePrivate
Founded2012
LocationHamburg, Germany
StagePhase 2
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile